BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//https://www.takethedate.it///NONSGML kigkonsult.se iCalcreator 2.10.15//
METHOD:PUBLISH
BEGIN:VEVENT
UID:20260409T012427CEST-9906nJDG0R@https://www.takethedate.it/
DTSTAMP:20260408T232427Z
DESCRIPTION:We are delighted to invite you to the debate organised by PubAf
 fairs Bruxelles which will be held on Wednesday the 22nd of November at 19
 .00 at the premises of Science14 Atrium\, rue de la Science\, 14-B\, Bruss
 els. The event will consist of a debate about whether incentives in the bi
 opharmaceutical industry are a hindrance or a benefit for Europe’s global 
 competitiveness.  Although speakers and event details will be announced in
  the coming days\, we are publishing this event now to make sure you save 
 the date.\nAbout the debate\nThe European Commission’s Communication on ‘I
 nvesting in a smart\, innovative and sustainable industry – A renewed EU I
 ndustrial Policy Strategy’ was announced in the European Commission Presid
 ent Juncker’s September 2017 State of the Union address. The speech and th
 e corresponding new Industrial Policy Strategy place considerable emphasis
  on innovation. At the same time the European Commission\, as requested by
  EU member states in the EU Council Conclusions from June 2016\, is curren
 tly analysing if the IP incentives and rewards system for the biopharmaceu
 tical industry is fit for purpose. This includes assessing the impact of e
 xisting incentives on innovation\, availability\, accessibility and health
  systems sustainability. The primary question being asked is if incentives
  are helping to bring innovative new treatments to patients in areas of un
 met medical needs.\nThe sustainability of healthcare expenditures is an es
 sential question for every EU member state. At the same time\, a change in
  the current IP incentives system would have an impact on Europe’s global 
 competitiveness\, the innovative biopharma industry\, and the viability of
  European public-private partnerships in research. At stake are much neede
 d high-skilled jobs and economic growth in Europe. Some commentators have 
 argued that market exclusivity under the current IP regime is hindering co
 mpetition\, while others have pointed to the fact that a strong and predic
 table IP framework is needed to ensure investment into complex and high-ri
 sk areas such as biopharma innovation.\nThe assessment of the possible imp
 act of changing the existing IP incentives on Europe’s global competitiven
 ess\, on patient’s access to innovative medicines\, and on future innovati
 on in European biopharma is crucial\, especially in light of the new EU in
 dustrial policy strategy. Can Europe lead the world in life sciences\, wit
 h its citizens first to benefit from the biologic and genomic revolution? 
 Competitiveness of Europe and the biopharmaceutical industry: Are incentiv
 es a hindrance or a benefit?\nThis event will be held under the Chatham Ho
 use Rule. Participants are free to use the information received but neithe
 r the identity nor the affiliation of the attendees may be revealed. For t
 his reason\, unless explicitly authorised by PubAffairs Bruxelles\, the fi
 lming and/or the recording of the event by any means are strictly forbidde
 n.\nThe event will commence with a welcome drink at 7h00 pm\, followed by 
 a panel debate at 7.30 pm. After the panel debate there will be an opportu
 nity for questions and discussions.
\nWe look forward to seeing you at 7h0
 0 pm on the 22nd of November at Science14 Atrium\, rue de la Science 14-B\
 , Brussels.\nAll our debates are followed by a drink in a convivial atmosp
 here. https://www.takethedate.it/Eventi/613-competitiveness-of-europe-and-
 the-biopharmaceutical-industry-are-incentives-a-hindrance-or-a-benefit.htm
 l
DTSTART:20171122T180000Z
DTEND:20171122T200000Z
LOCATION:Science14 Atrium (Bruxelles)
SUMMARY:Competitiveness of Europe and the biopharmaceutical industry: Are i
 ncentives a hindrance or a benefit?
URL:https://www.takethedate.it/Eventi/613-competitiveness-of-europe-and-the
 -biopharmaceutical-industry-are-incentives-a-hindrance-or-a-benefit.html
END:VEVENT
END:VCALENDAR